Clinical trials: Pulmonary Disease, Chronic Obstructive
Pulmonary Disease, Chronic Obstructive
Clinical Study to Assess the Effects of SRT2104 and Prednisolone on Biomarkers in Blood in Healthy Volunteers
The primary purpose of this study is to assess the pharmacodynamic effect of single, oral doses of SRT2104 (250 mg, 500 mg, 1000 mg, 2000 mg) and prednisolone as measured by levels of ex vivo LPS-induced TNF-alpha production in…
- Trial name
- NCT00920660
- Testing
- 0.25g SRT2104, Prednisolone, 0.5g SRT2104
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease (COPD) With Cachexia
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
This study will assess the pharmacodynamics, pharmacokinetics, safety and tolerability of BYM338 in patients with COPD and cachexia. The primary outcome will be a change in thigh muscle volume compared to placebo.
- Trial name
- NCT01669174
- Testing
- BYM338
- Where
- 9 sites in United States, Netherlands and 1 more
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Symbicort in Chronic Obstructive Pulmonary Disease
Under daily routine conditions and without any intervention by the sponsor regarding the selection of subjects, diagnostic procedures, therapeutic decisions (medicinal and non- medicinal therapy, dose, duration, etc.), routine…
- Trial name
- SYMBOL (NCT00611520)
- Volunteers
- 64,730 people
- Sponsor
- AstraZeneca
COPD, Cachexia
Pilot Study of Safety and Tolerability of Nutrifriend Cachexia in COPD Cachexia
SF-K002 is a pilot study in patients with moderate to severe COPD suffering from involuntary weight loss. The study is 12 weeks, double-blinded, placebo controlled and the main objective is to study the safety and tolerability of…
- Trial name
- NCT02442908
- Testing
- Nutrifriend Cachexia
- Where
- 4 sites in Sweden
- Volunteers
- 45 people
- Sponsor
- Smartfish AS
Osteoarthritis, Knee, Osteoarthritis, Hip
A Prospective Multicenter Longitudinal Cohort Study of the Mymobility Platform
Post-market prospective, multi-center longitudinal study to determine if mobile application-guided education and exercise paired with accurate and sensitive activity monitoring, captured from consumer wearables, can provide a…
- Trial name
- NCT03737149
- Testing
- mymobility with Apple Watch
- Where
- 30 sites in United States, Australia and 2 more
- Volunteers
- 6,559 people
- Sponsor
- Zimmer Biomet
Chronic Obstructive Pulmonary Disease, Chronic Bronchitis
To Evaluate the Long-term Safety of (R,R)-Formoterol in Subjects With COPD
The purpose of this study is to determine the long-term safety of arformoterol over a period of 12 months in subjects with COPD
- Conditions
- Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema
- Trial name
- NCT00064415
- Testing
- arformoterol, Salmeterol
- Where
- 90 sites in United States
- Volunteers
- 799 people
- Sponsor
- Sumitomo Pharma America, Inc.
Chronic Obstructive Pulmonary Disease (COPD)
Utility of Remote Lung Auscultation in Transitions of Care After Pulmonary Exacerbations of COPD
Listening to breath sounds with the stethoscope/auscultation is used by pulmonary physicians in conjunction with pulmonary function, signs and symptoms, oxygen saturation and diagnostic testing to admit, follow and discharge…
- Trial name
- NCT05661435
- Testing
- RESP Biosensor
- Where
- 2 sites in United States
- Sponsor
- Strados Labs, Inc.
Chronic Obstructive Pulmonary Disease
Safety Study to Evaluate MN-221 in Chronic Obstructive Pulmonary Disease (COPD) Patients
In MediciNova's clinical development plan for MN-221, it was recognized that treatment of COPD exacerbations may necessitate more than one single i.v.
- Trial name
- NCT01551316
- Testing
- MN-221
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- MediciNova
Chronic Obstructive Pulmonary Disease (COPD)
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Cavosonstat Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: The purpose of this study is to to evaluate the efficacy and safety of Cavosonstat administered twice daily compared with Placebo for 24 Weeks in adult subjects with Chronic Obstructive Pulmonary Disease (COPD)…
- Trial name
- NCT04600778
- Testing
- Cavosonstat 5 mg, Cavosonstat 10 mg, Cavosonstat 25 mg
- Volunteers
- 108 people
- Sponsor
- GSNOR Therapeutics, Inc.
COPD, Chronic Obstructive Pulmonary Disease
A Study to Assess the Effects of PT001 and PT005 MDI on Specific Image Based Parameters in Subjects With Moderate to Severe COPD
To assess the effect of treatment with Glycopyronnium (GP) MDI administered twice daily (BID) and Formoterol Fumarate (FF) MDI administered BID on specific image-based airway volumes and resistance in subjects with moderate to…
- Trial name
- NCT02937584
- Testing
- GP MDI (PT001) 14.4 μg, FF MDI (PT005) 9.6 μg
- Where
- 2 sites in Belgium
- Volunteers
- 23 people
- Sponsor
- Pearl Therapeutics, Inc.
Chronic Obstructive Pulmonary Disease
Effect of ADC4022 Co-Administered With Budesonide on Pulmonary Inflammation in Subjects With Moderate to Severe COPD
The purpose of this study is to assess the tolerability and efficacy of inhaled theophylline (ADC4022) on markers of pulmonary inflammation (white blood cells) in induced sputum and in bronchial biopsy samples in subjects with…
- Trial name
- NCT00634413
- Testing
- Theophylline - ADC4022, Budesonide
- Where
- 8 sites in Poland, United Kingdom
- Volunteers
- 91 people
- Sponsor
- Pulmagen Therapeutics
Pulmonary Disease, Chronic Obstructive
Lung Function Changes Following the Addition of Formoterol to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Study to establish the lung function effects of added formoterol (12μg QD and BID) during 2-week periods to pharmacodynamic steady state of tiotropium(18μg QD)
- Trial name
- NCT02242240
- Testing
- Formoterol twice daily, Formoterol once daily, Tiotropium once daily
- Volunteers
- 95 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD
The primary objective of this study is to compare the effects of orally inhaled tiotropium + olodaterol fixed dose combination (2.5/5 µg; 5/5 µg) with placebo on exercise tolerance after 12 weeks of treatment in patients with…
- Trial name
- NCT01525615
- Testing
- Respimat inhaler, tiotropium+olodaterol (low dose), tiotropium + olodaterol (high dose)
- Where
- 60 sites in United States, Argentina and 8 more
- Volunteers
- 404 people
- Sponsor
- Boehringer Ingelheim
Chronic Graft-versus-host-disease
A Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHD
This is a Phase 1/2, Open-label, Dose Escalation study to investigate axatilimab in participants with active chronic graft versus host disease (cGVHD).
- Trial name
- NCT03604692
- Testing
- axatilimab
- Where
- 11 sites in United States
- Volunteers
- 41 people
- Sponsor
- Syndax Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Patient Registry of Roflumilast In Real Life
A patient registry to capture real life data and demonstrate the performance of roflumilast (Daxas®) in a standard clinical practice.
- Trial name
- NCT02015767
- Where
- 51 sites in Bulgaria, Greece and 4 more
- Volunteers
- 1,950 people
- Sponsor
- AstraZeneca
COPD
Comparison of 24 Hour Bronchodilator Efficacy of Tiotropium 18 mcg Delivered Via DISCAIR Versus SPIRIVA 18 µg Delivered Via HANDIHALER® in Patients With Moderate to Severe COPD
The objective of this study is to compare the bronchodilator efficacy a of tiotropium inhalation via DISCAIR (18 mcg once daily) and SPIRIVA HANDIHALER® (18 mcg once daily) in patients with moderate to severe chronic obstructive…
- Trial name
- NCT02541006
- Testing
- Tiotropium 18 mcg
- Volunteers
- 58 people
- Sponsor
- Neutec Ar-Ge San ve Tic A.Ş
COPD
Pharmacokinetic Interaction Study of Glycopyrrolate and Formoterol in Healthy Volunteers
This study will be carried out in healthy volunteers with the primary objective to evaluate the pharmacokinetic interaction between Glyco and Formoterol administered using a pressurised metered dose inhaler (pMDI).
- Trial name
- TRIPLE 1 (NCT01398111)
- Testing
- Glycopyrrolate + Formoterol, Glycopyrrolate, Formoterol
- Where
- Belgium
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
Chronic Obstructive Pulmonary Disease (COPD)
QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations)
This study will assess the efficacy, safety and tolerability of QVA149 in patients with moderate to very severe COPD.
- Trial name
- NCT01782326
- Testing
- QVA149, Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS)
- Where
- 499 sites in Argentina, Austria and 41 more
- Volunteers
- 3,362 people
- Sponsor
- Novartis Pharmaceuticals
Alpha1-Antitrypsin Deficiency
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency
The purpose of this study is to evaluate the safety and tolerability of 72 milligrams per kilogram (mg/kg) and 180 mg/kg Alpha-1 15%, administered as a single-dose subcutaneous (SC) infusion and subsequently as weekly SC…
- Trial name
- NCT04722887
- Testing
- Alpha-1 15%, Liquid Alpha1-Proteinase Inhibitor (Human)
- Where
- 5 sites in United States
- Volunteers
- 17 people
- Sponsor
- Grifols Therapeutics LLC
Pulmonary Disease, Chronic Obstructive
12-week Treatment With Inhaled Tiotropium (18 mcg Once Daily) on Lung Function and Static Lung Volumes in Stable, Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients. Correlation to Dyspnoea Scales
Determine the effect of 12-week treatment with inhaled tiotropium bromide on lung function and static lung volumes, correlate this effect with dyspnoea in COPD patients.
- Trial name
- NCT02172378
- Testing
- Tiotropium inhalation capsules
- Volunteers
- 116 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.